AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28831548 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 68
Study 25325508 — intervention group
Group type: EXPERIMENTAL
Intervention: Home single-channel nasal pressure (HNP)
Number of subjects: 787
Study 23000525 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified method for complete denture fabrication (Group S)
Number of subjects: 39
Study 23000525 — intervention group
Group type: COMPARATOR
Intervention: Conventional method for complete denture fabrication (Group C)
Number of subjects: 39
Study 21303732 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-MPH), mean daily dose 84.6±31.6 mg (1.04±0.29 mg/kg)
Number of subjects: 87
Study 21303732 — intervention group
Group type: COMPARATOR
Intervention: Placebo, mean daily dose 100.5±21.9 mg (1.20±0.11 mg/kg)
Number of subjects: 87
Study 21303732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OROS-MPH and Placebo
Number of subjects: 87
Study 19530576 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg intramuscular every 12 hours for 2 doses
Number of subjects: 80
Study 19530576 — intervention group
Group type: COMPARATOR
Intervention: Standard rescue drugs (Tramadol)
Number of subjects: 80
Study 17344500 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 149
Study 17344500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 12901874 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (250 mg/day)
Number of subjects: 0
Study 10475595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine 5% cream (EMLA)
Number of subjects: 120
Study 10475595 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 120
Study 8712153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine administration
Number of subjects: 12
Study 8712153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1680327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol (0.2 mg) in Autohaler
Number of subjects: 17
Study 1680327 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (0.1 mg) in customary metered-dose inhaler
Number of subjects: 17
Study 7040820 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with DTIC plus intradermal BCG
Number of subjects: 60
Study 7040820 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl‐CCNU plus intradermal BCG
Number of subjects: 60
Study 7040820 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (both groups)
Number of subjects: 60
Study 7040820 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 60
Study 30920952 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical reasoning curriculum (six interactive online modules and a skills-based workshop)
Number of subjects: 0
Study 29094315 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 µg once daily
Number of subjects: 236
Study 29094315 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium/Olodaterol (TIO/OLO) 5/5 µg once daily
Number of subjects: 236
Study 29094315 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol (UMEC/VI)
Number of subjects: 236
Study 29094315 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium/Olodaterol (TIO/OLO)
Number of subjects: 236
Study 26433562 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced standard treatment combined with the computer‐based therapeutic education system (TES)
Number of subjects: 160
Study 26433562 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone maintenance treatment
Number of subjects: 160
Study 23713301 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum-blossom needle therapy
Number of subjects: 50
Study 23713301 — intervention group
Group type: COMPARATOR
Intervention: Medication group (clomifene and HCG)
Number of subjects: 50
Study 21282548 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Self‐Report Assessment‐Cancer (ESRA‐C) provided to clinicians before visits (n = 327)
Number of subjects: 660
Study 21282548 — intervention group
Group type: COMPARATOR
Intervention: No summary provided to clinicians (Control group, n = 333)
Number of subjects: 660
Study 21282548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ESRA-C and Control)
Number of subjects: 660
Study 19917523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) and Vitamin C and E (VCE) supplementation
Number of subjects: 80
Study 19917523 — intervention group
Group type: COMPARATOR
Intervention: No HRT treatment (Control)
Number of subjects: 80
Study 15975736 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.0 mg/kg)
Number of subjects: 0
Study 15975736 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg)
Number of subjects: 0
Study 15975736 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine (20 mg)
Number of subjects: 0
Study 15975736 — intervention group
Group type: COMPARATOR
Intervention: mCPP (0.75 mg/kg)
Number of subjects: 0
Study 15975736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15285969 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety therapy
Number of subjects: 107
Study 15285969 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention therapy
Number of subjects: 107
Study 15285969 — intervention group
Group type: COMPARATOR
Intervention: Standard Community Care
Number of subjects: 107
Study 10719574 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arroz caldo with 14.84 g total dietary fiber (TDF)
Number of subjects: 10
Study 10719574 — intervention group
Group type: COMPARATOR
Intervention: Control arroz caldo with 3.45 g total dietary fiber (TDF)
Number of subjects: 10
Study 10719574 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arroz caldo
Number of subjects: 10
Study 8548716 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg per day
Number of subjects: 0
Study 8548716 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (generic)
Number of subjects: 0
Study 8548716 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 8548716 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 1685533 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% dapiprazole
Number of subjects: 90
Study 1685533 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% acetylcholine
Number of subjects: 90
Study 1685533 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 90
Study 6972401 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified ragweed extract (RW)
Number of subjects: 67
Study 6972401 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde polymer of ragweed extract (PRW)
Number of subjects: 67
Study 6972401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 30707225 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated antenatal betamethasone treatment
Number of subjects: 988
Study 30707225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 988
Study 29490637 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 50
Study 29490637 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 26727697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy combined with drug therapy (Group A)
Number of subjects: 98
Study 26727697 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy alone (Group B)
Number of subjects: 98
Study 24083998 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CMV serointensity in patients with schizophrenia
Number of subjects: 289
Study 24083998 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CMV serointensity in patients with bipolar disorder
Number of subjects: 289
Study 24083998 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 289
Study 22469291 — intervention group
Group type: EXPERIMENTAL
Intervention: Up front surgery of the breast tumor followed by systemic therapy
Number of subjects: 516
Study 22469291 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy followed by delayed local treatment of the breast tumor if clinically indicated
Number of subjects: 516
Study 20413364 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus fenofibric acid 135 mg daily for 18 months
Number of subjects: 0
Study 20413364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17507311 — intervention group
Group type: EXPERIMENTAL
Intervention: Enediyne compounds
Number of subjects: 0
Study 15610940 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) isradipine 15 mg
Number of subjects: 8
Study 15610940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) isradipine 30 mg
Number of subjects: 8
Study 15610940 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IR and SR isradipine
Number of subjects: 8
Study 12137829 — intervention group
Group type: EXPERIMENTAL
Intervention: ProstaLund Feedback Treatment (PLFT)
Number of subjects: 154
Study 12137829 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 154
Study 10202826 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP + ZDV
Number of subjects: 29
Study 10202826 — intervention group
Group type: EXPERIMENTAL
Intervention: ddl + ZDV
Number of subjects: 29
Study 10202826 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP + ddl + ZDV
Number of subjects: 29
Study 10202826 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination regimen (NVP + ddl + ZDV)
Number of subjects: 29
Study 10202826 — intervention group
Group type: EXPERIMENTAL
Intervention: Virological responders (long-term)
Number of subjects: 29
Study 10202826 — intervention group
Group type: COMPARATOR
Intervention: Virological failure
Number of subjects: 29
Study 7472658 — intervention group
Group type: COMPARATOR
Intervention: Continued exclusive breast-feeding to 6 months (EBF)
Number of subjects: 141
Study 7472658 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months, with ad libitum nursing 4-6 months (SF)
Number of subjects: 141
Study 7472658 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months, with maintenance of baseline nursing frequency 4-6 months (SF-M)
Number of subjects: 141
Study 30642252 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-Exercise (T&E) programme
Number of subjects: 405
Study 30642252 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme
Number of subjects: 405
Study 30642252 — intervention group
Group type: COMPARATOR
Intervention: Helsana programme (recommendation-booklet and exercise-cards)
Number of subjects: 405
Study 28503818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray
Number of subjects: 200
Study 28503818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 200
Study 28503818 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine cream
Number of subjects: 200
Study 28503818 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 26713003 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod
Number of subjects: 74
Study 26713003 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 74
Study 23729929 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 48
Study 23729929 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 48
Study 22177021 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of health education and sexual health services
Number of subjects: 739
Study 22177021 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education only
Number of subjects: 739
Study 22177021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health services only
Number of subjects: 739
Study 22177021 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 739
Study 19699566 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive direct anterior approach (DA)
Number of subjects: 33
Study 19699566 — intervention group
Group type: COMPARATOR
Intervention: Traditional anterolateral approach (AL)
Number of subjects: 33
Study 17383264 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat- and saturated fat-modified dietary intervention
Number of subjects: 653
Study 17383264 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 653
Study 15502065 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Unique (LMA‐U)
Number of subjects: 90
Study 15502065 — intervention group
Group type: COMPARATOR
Intervention: Soft Seal laryngeal mask airway (SSLM)
Number of subjects: 90
Study 11887672 — intervention group
Group type: EXPERIMENTAL
Intervention: System A
Number of subjects: 0
Study 11887672 — intervention group
Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 0
Study 11887672 — intervention group
Group type: EXPERIMENTAL
Intervention: System C
Number of subjects: 0
Study 9543326 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline
Number of subjects: 30
Study 9543326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8165045 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (high cholesterol, low phytoestrogen)
Number of subjects: 33
Study 8165045 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk‐based formula (zero cholesterol, high phytoestrogen)
Number of subjects: 33
Study 8165045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk‐based formula (low cholesterol, low phytoestrogen)
Number of subjects: 33
Study 8165045 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified soy milk‐based formula (low cholesterol, high phytoestrogen)
Number of subjects: 33
Study 8165045 — intervention group
Group type: COMPARATOR
Intervention: Modified soy milk‐based formula
Number of subjects: 33
Study 3243094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1.5 g and 1.2 g
Number of subjects: 683
Study 3243094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 2 g (single dose)
Number of subjects: 683
Study 3243094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 2 g for 10 days
Number of subjects: 683
Study 3243094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil
Number of subjects: 683
Study 3243094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1 g
Number of subjects: 683
Study 3243094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 2 g
Number of subjects: 683
Study 31996614 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (HF) training (3 days per week)
Number of subjects: 30
Study 31996614 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency (LF) training (1 day per week)
Number of subjects: 30
Study 31996614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HF and LF protocols
Number of subjects: 30
Study 30224019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 2-3 mg daily
Number of subjects: 124
Study 30224019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 27330698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 40
Study 27330698 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg bid for 3 weeks
Number of subjects: 40
Study 25907848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive remedial teaching using multisensory reading program with greater kinesthetic demands
Number of subjects: 49
Study 25907848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive remedial teaching using multisensory reading program with greater visual-spatial demands
Number of subjects: 49
Study 25907848 — intervention group
Group type: COMPARATOR
Intervention: Control group - wait-list IRD (no treatment)
Number of subjects: 49
Study 25907848 — intervention group
Group type: COMPARATOR
Intervention: Control group - typically developing readers (no treatment)
Number of subjects: 49
Study 24047126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 0
Study 24047126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg
Number of subjects: 0
Study 24047126 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 0
Study 24047126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20961406 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary cognitive behavioural treatment programme (11 sessions over 3 months)
Number of subjects: 60
Study 20961406 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (invited for the programme 6 months after the intervention group)
Number of subjects: 60
Study 20961406 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary cognitive behavioural treatment programme
Number of subjects: 60
Study 18242454 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocaine 1%
Number of subjects: 56
Study 18242454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate after Xylocaine
Number of subjects: 56
Study 18242454 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine after Cyclopentolate
Number of subjects: 56
Study 18242454 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine after Xylocaine
Number of subjects: 56
Study 18242454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate after Phenylephrine
Number of subjects: 56
Study 18242454 — intervention group
Group type: COMPARATOR
Intervention: Intracameral mydriatics with cyclopentolate
Number of subjects: 56
Study 16023336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubing group (n=140)
Number of subjects: 295
Study 16023336 — intervention group
Group type: COMPARATOR
Intervention: No-tubing group (n=155)
Number of subjects: 295
Study 12826039 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (T)
Number of subjects: 0
Study 12826039 — intervention group
Group type: COMPARATOR
Intervention: Sequential methotrexate and 5‐fluorouracil (MF)
Number of subjects: 0
Study 12826039 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline QoL
Number of subjects: 0
Study 10806602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban with ASA
Number of subjects: 24
Study 10806602 — intervention group
Group type: COMPARATOR
Intervention: Sibrafiban alone
Number of subjects: 24
Study 10806602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban with heparin
Number of subjects: 24
Study 10806602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban with ASA and heparin
Number of subjects: 24
Study 8658370 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 300 micrograms
Number of subjects: 8
Study 8658370 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 72 micrograms
Number of subjects: 8
Study 8658370 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 8
Study 8658370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1380609 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg
Number of subjects: 20
Study 1380609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6151044 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 15
Study 6151044 — intervention group
Group type: COMPARATOR
Intervention: Glutethimide (placebo)
Number of subjects: 15
Study 30836981 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of renin-angiotensin system inhibitors (RASi)
Number of subjects: 2222
Study 30836981 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of renin-angiotensin system inhibitors (RASi) 48 hours before surgery
Number of subjects: 2222
Study 29369904 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP treatment (1.0 × 10 platelets/cm sprayed on wound)
Number of subjects: 27
Study 29369904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 27
Study 27553576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulthiame
Number of subjects: 43
Study 27553576 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 43
Study 27553576 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment mentioned)
Number of subjects: 43
Study 24429541 — intervention group
Group type: EXPERIMENTAL
Intervention: High-palmitic acid (HPA) diet
Number of subjects: 18
Study 24429541 — intervention group
Group type: COMPARATOR
Intervention: Low-palmitic acid and high-oleic acid (HOA) diet
Number of subjects: 18
Study 22709778 — intervention group
Group type: COMPARATOR
Intervention: Physician's dietary advice (PI group) (n=42)
Number of subjects: 86
Study 22709778 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's dietary advice plus personalized diet management by a registered dietitian (DM group) (n=44)
Number of subjects: 86
Study 20714165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C
Number of subjects: 34
Study 17608755 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/day) for 36 months
Number of subjects: 22
Study 17608755 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 22
Study 15455827 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led labour care model
Number of subjects: 0
Study 15455827 — intervention group
Group type: COMPARATOR
Intervention: Midwife-and-doctor group
Number of subjects: 0
Study 11169006 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialyzer membrane (polyamide)
Number of subjects: 6
Study 11169006 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialyzer membrane (cellulosic/cuprophan)
Number of subjects: 6
Study 11169006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high-flux and low-flux dialyzer membranes
Number of subjects: 6
Study 9699399 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic magnets (test)
Number of subjects: 8
Study 9699399 — intervention group
Group type: COMPARATOR
Intervention: Demagnetized magnet (control)
Number of subjects: 8